Clinical and economic implications of urinary tract infections

References

• Cardwell SM, Crandon JL, Nicolau DP, et al. Epidemiology and economics of adult patients hospitalized with urinary tract infections. Hosp Pract. 2016;44(1):33–40.
   PubMedGoogle Scholar
• MacVane SH, Tuttle LO, Nicolau DP. Demography and burden of care associated with patients readmitted for urinary tract infection. J Microbiol Immunol Infect. 2015;48:517–524.
   PubMedGoogle Scholar
• Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med. 2012;366(11):1028–1037.
   PubMed Web of Science ®Google Scholar
• Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–663.
   PubMed Web of Science ®Google Scholar
• Finer G, Landau D. Pathogenesis of urinary tract infections with normal female anatomy. Lancet Infect Dis. 2004;4(10):631–635.
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. Bladder infection (urinary tract infection - UTI) in adults. 2016. Available from: https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-infection-uti-in-adults
   Google Scholar
• Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guideline for prevention of catheterassociated urinary tract infections 2009. 2017 Feb: 1-61. Available from: https://www.cdc.gov/infectioncontrol/guidelines/cauti/
   Google Scholar
• MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. J Hosp Med. 2014;9:232–238.
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Badal RE, Hoban DJ, et al. Antimicrobial susceptibility of inpatient urinary tract isolates of Gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther. 2013;35:872–877.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Hackel M, Badal R, et al. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel, Switzerland). 2013;6:1335–1346.
   PubMedGoogle Scholar
• Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):103–120.
   PubMed Web of Science ®Google Scholar
• Briongos-Figuero LS, Gomez-Traveso T, Bachiller-Luque P, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;66(9):891–896.
   PubMed Web of Science ®Google Scholar
• Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum-beta-lactamase-producing uropathogens in urinary tract infection. Korean J Urol. 2010;51(7):492–497.
   PubMedGoogle Scholar
• Zmarlicka MT, Cardwell SM, Crandon JL, et al. Evaluation of a disease state management guideline for urinary tract infection. Int J Antimicrob Agents. 2016;47:451–456.
   PubMed Web of Science ®Google Scholar
• Gibson K, Toscano J. Urinary tract infection update. Am J Clin Med. 2012;9(2):82-86. Available from: http://www.aapsus.org/wp-content/uploads/uti82.pdf
   Google Scholar
• Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta- lactamase-producing gram-negative organisms. J Antimicrob Chemother. 2010;65:1510–1513.
   PubMed Web of Science ®Google Scholar
• Veve MP, Wagner JL, Kenney RM, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Int J Antimicrob Agents. 2016;48:56–60.
   PubMed Web of Science ®Google Scholar
• AVYCAZ (ceftazidime and avibactam) [package insert]. Dublin: Allergan Pharmaceuticals; 2017.
   Google Scholar
• ZERBAXA (ceftolozane/tazobactam) [package insert]. Kenilworth (NJ): Merck Pharmaceuticals; 2014.
   Google Scholar
• Thaden JT, Pogue JM, Kaye KS, et al. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence. 2017;8:403–416.
   PubMed Web of Science ®Google Scholar
• De Maio Carrilho C, De Oliveira L, Gaudereto J, et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis. 2016 Nov 3;16(1):629. DOI:10.1186/s12879-016-1979-z.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, et al. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017 Apr 17;17(1):279. doi: 10.1186/s12879-017-2383-z.
   PubMed Web of Science ®Google Scholar
• Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antibiotic therapy. Clin Infect Dis. 2004;38:1651–1672.
   PubMed Web of Science ®Google Scholar
• Laupland KB, Valiquette L. Outpatient parenteral antimicrobial therapy. Can J Infect Dis Med Microbiol. 2013;24:9–11.
   PubMed Web of Science ®Google Scholar
• Halilovic J, Christensen CL, Nguyen HH. Managing an outpatient parenteral antibiotic therapy team: challenges and solutions. Ther Clin Risk Manag. 2014;10:459–465.
   PubMed Web of Science ®Google Scholar